Logo image of ALBIO.PA

BIOSYNEX (ALBIO.PA) Stock Fundamental Analysis

EPA:ALBIO - FR0011005933 - Common Stock

1.18 EUR
-0.01 (-0.84%)
Last: 9/9/2025, 7:00:00 PM
Fundamental Rating

2

Taking everything into account, ALBIO scores 2 out of 10 in our fundamental rating. ALBIO was compared to 58 industry peers in the Health Care Equipment & Supplies industry. ALBIO has a bad profitability rating. Also its financial health evaluation is rather negative. ALBIO has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALBIO had negative earnings in the past year.
In the past year ALBIO has reported a negative cash flow from operations.
In multiple years ALBIO reported negative net income over the last 5 years.
In multiple years ALBIO reported negative operating cash flow during the last 5 years.
ALBIO.PA Yearly Net Income VS EBIT VS OCF VS FCFALBIO.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

1.2 Ratios

ALBIO has a worse Return On Assets (-22.24%) than 74.14% of its industry peers.
With a Return On Equity value of -53.75%, ALBIO is not doing good in the industry: 75.86% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -22.24%
ROE -53.75%
ROIC N/A
ROA(3y)-10.54%
ROA(5y)6.39%
ROE(3y)-24.67%
ROE(5y)7.07%
ROIC(3y)N/A
ROIC(5y)N/A
ALBIO.PA Yearly ROA, ROE, ROICALBIO.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60

1.3 Margins

ALBIO has a Gross Margin (56.78%) which is comparable to the rest of the industry.
ALBIO's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for ALBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 56.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.7%
GM growth 5Y-0.09%
ALBIO.PA Yearly Profit, Operating, Gross MarginsALBIO.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40

More info and screens

1

2. Health

2.1 Basic Checks

ALBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALBIO has about the same amount of shares outstanding.
The number of shares outstanding for ALBIO has been increased compared to 5 years ago.
Compared to 1 year ago, ALBIO has a worse debt to assets ratio.
ALBIO.PA Yearly Shares OutstandingALBIO.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
ALBIO.PA Yearly Total Debt VS Total AssetsALBIO.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

ALBIO has an Altman-Z score of 0.26. This is a bad value and indicates that ALBIO is not financially healthy and even has some risk of bankruptcy.
ALBIO has a Altman-Z score of 0.26. This is in the lower half of the industry: ALBIO underperforms 70.69% of its industry peers.
A Debt/Equity ratio of 0.19 indicates that ALBIO is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.19, ALBIO is in the better half of the industry, outperforming 68.97% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z 0.26
ROIC/WACCN/A
WACC6.54%
ALBIO.PA Yearly LT Debt VS Equity VS FCFALBIO.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

ALBIO has a Current Ratio of 0.71. This is a bad value and indicates that ALBIO is not financially healthy enough and could expect problems in meeting its short term obligations.
ALBIO has a worse Current ratio (0.71) than 89.66% of its industry peers.
ALBIO has a Quick Ratio of 0.71. This is a bad value and indicates that ALBIO is not financially healthy enough and could expect problems in meeting its short term obligations.
ALBIO has a Quick ratio of 0.35. This is amonst the worse of the industry: ALBIO underperforms 91.38% of its industry peers.
Industry RankSector Rank
Current Ratio 0.71
Quick Ratio 0.35
ALBIO.PA Yearly Current Assets VS Current LiabilitesALBIO.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

ALBIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.27%.
ALBIO shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.76%.
The Revenue has been growing by 24.22% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-12.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.69%
Revenue 1Y (TTM)8.76%
Revenue growth 3Y-35.81%
Revenue growth 5Y24.22%
Sales Q2Q%-5.76%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y475%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year15.05%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALBIO.PA Yearly Revenue VS EstimatesALBIO.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
ALBIO.PA Yearly EPS VS EstimatesALBIO.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2019 2020 2021 2023 2024 2025 0 2 -2 4 6 8

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

ALBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 2.49 indicates a rather cheap valuation of ALBIO.
ALBIO's Price/Forward Earnings ratio is rather cheap when compared to the industry. ALBIO is cheaper than 100.00% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.59, ALBIO is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 2.49
ALBIO.PA Price Earnings VS Forward Price EarningsALBIO.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALBIO.PA Per share dataALBIO.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALBIO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOSYNEX

EPA:ALBIO (9/9/2025, 7:00:00 PM)

1.18

-0.01 (-0.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-17 2025-07-17
Earnings (Next)N/A N/A
Inst Owners0.46%
Inst Owner ChangeN/A
Ins Owners5.7%
Ins Owner ChangeN/A
Market Cap22.13M
Analysts86.67
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 2.49
P/S 0.22
P/FCF N/A
P/OCF N/A
P/B 0.27
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.37
EYN/A
EPS(NY)0.47
Fwd EY40.15%
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.54
OCFYN/A
SpS5.39
BVpS4.3
TBVpS-1.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.24%
ROE -53.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 56.78%
FCFM N/A
ROA(3y)-10.54%
ROA(5y)6.39%
ROE(3y)-24.67%
ROE(5y)7.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.7%
GM growth 5Y-0.09%
F-Score4
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 23.57%
Cap/Sales 4.79%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.71
Quick Ratio 0.35
Altman-Z 0.26
F-Score4
WACC6.54%
ROIC/WACCN/A
Cap/Depr(3y)143.09%
Cap/Depr(5y)301.13%
Cap/Sales(3y)20.88%
Cap/Sales(5y)14.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.69%
EPS Next Y475%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)8.76%
Revenue growth 3Y-35.81%
Revenue growth 5Y24.22%
Sales Q2Q%-5.76%
Revenue Next Year15.05%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y5.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2216.67%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y69.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.84%
OCF growth 3YN/A
OCF growth 5YN/A